Open-Label Expanded Access for Ebola-Infected Patients to Receive Human mAb Ansuvimab as Therapeutic or for HR PEP
Condition:   Ebola Virus Disease, Ebola Virus Infection, Ebola Intervention:   Drug: Ansuvimab Sponsors:   Ridgeback Biotherapeutics, LP;   Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo No longer available (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 5, 2021 Category: Research Source Type: clinical trials

Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study)
Conditions:   Ebola Virus Disease;   Ebola;   Hiv Intervention:   Biological: Ad26.ZEBOV Sponsor:   London School of Hygiene and Tropical Medicine Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 1, 2021 Category: Research Source Type: clinical trials